Vepoloxamer增强tPA对急性缺血性卒中的纤溶作用
本研究在大鼠栓塞性卒中模型中,于大脑中动脉闭塞后4小时给予vepoloxamer联合tPA、单用vepoloxamer、单用tPA或生理盐水。单用tPA未减少梗死体积,反而加重微血管血栓和血管渗漏;联合治疗减少梗死体积32%并改善神经功能,不增加明显出血。
要点
- 单用tPA在4小时时间窗未减少梗死体积,反而加重血栓和渗漏。
- Vepoloxamer单用减少梗死体积25%并改善脑灌注。
- 联合治疗减少梗死体积32%、改善神经功能且不增加出血。
核心结论
- Vepoloxamer联合tPA在大鼠急性缺血性卒中模型中发挥强效溶栓作用,并减轻tPA加重的血小板外泌体促血栓效应。
研究设计与样本
- 雄性Wistar大鼠栓塞性大脑中动脉闭塞模型,于闭塞后4小时分别给予vepoloxamer联合tPA、单用vepoloxamer、单用tPA或生理盐水。
主要发现
- 单用tPA未减少梗死体积,且与生理盐水相比加重微血管血栓和血管渗漏。
- Vepoloxamer单用减少梗死体积25%并改善脑灌注。
- 联合治疗减少梗死体积32%并改善神经功能,不增加明显出血发生率。
- 联合治疗较单用vepoloxamer进一步减少继发性血栓和tPA加重的微血管渗漏,并改善脑灌注,与血清活性PAI-1水平及缺血脑组织tPA上调的PAI-1大幅降低相关。
- tPA处理大鼠的血小板外泌体增加脑内皮屏障通透性和内皮细胞PAI-1、TF蛋白水平,而联合治疗的血小板外泌体减轻tPA加重的内皮通透性并降低内皮细胞PAI-1和TF水平。
临床怎么用
- 在4小时时间窗内,vepoloxamer联合tPA可增强溶栓效果并减轻tPA相关促血栓和渗漏效应,但尚需临床研究验证。
局限性
- 本研究为大鼠栓塞性卒中模型,结果不能直接外推至临床患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Thrombolytic treatment of acute ischemic stroke with tPA (tissue-type plasminogen activator) is hampered by its narrow therapeutic window and potential hemorrhagic complication. Vepoloxamer is a nonionic surfactant that exerts potent hemorheologic and antithrombotic properties in various thrombotic diseases. The current study investigated the effect of vepoloxamer on tPA treatment in a rat model of embolic stroke. Methods- Male Wistar rats subjected to embolic middle cerebral artery occlusion were treated with the combination of vepoloxamer and tPA, vepoloxamer alone, tPA alone, or saline initiated 4 hours after middle cerebral artery occlusion. Results- Monotherapy with tPA did not reduce infarct volume, and adversely potentiated microvascular thrombosis and vascular leakage compared with the saline treatment. Vepoloxamer monotherapy reduced infarct volume by 25% and improved brain perfusion. However, the combination treatment with vepoloxamer and tPA significantly reduced infarct volume by 32% and improved neurological function, without increasing the incidence of gross hemorrhage. Compared with vepoloxamer alone, the combination treatment with vepoloxamer and tPA robustly reduced secondary thrombosis and tPA-augmented microvascular leakage and further improved brain perfusion, which was associated with substantial reductions of serum active PAI-1 (plasminogen activator inhibitor-1) level and tPA-upregulated PAI-1 in the ischemic brain. Mechanistically, exosomes derived from platelets of ischemic rats treated with tPA-augmented cerebral endothelial barrier permeability and elevated protein levels of PAI-1 and TF (tissue factor) in the endothelial cells, whereas exosomes derived from platelets of rats subjected to the combination treatment with vepoloxamer and tPA diminished endothelial permeability augmented by tPA and fibrin and reduced PAI-1 and TF levels in the endothelial cells. Conclusions- The combination treatment with vepoloxamer and tPA exerts potent thrombolytic effects in rats subjected to acute ischemic stroke. Vepoloxamer reduces tPA-aggravated prothrombotic effect of platelet-derived exosomes on cerebral endothelial cells, which may contribute to the therapeutic effect of the combination treatment.
引用
- Wang C, Huang R, Li C, et al. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke. Stroke. 2019. PMID: 31587657. doi:10.1161/STROKEAHA.119.026049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。